Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Measurement of infliximab and anti-drug antibody levels in patients with inflammatory bowel disease

  • At: 2018 FIP Congress in Glasgow (Scotland)
  • Type: Presentation
  • By: MASUI, Sho (Kyoto University Hospital, Japan)
  • Co-author(s): Sho Masui: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan;Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan
    Atsushi Yonezawa: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan;Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan
    Yasuaki Ikemi: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
    Masaya Denda: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
    Yuki Otani: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
    Satoshi Imai: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
    Makoto Hayakari: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
    Noriko Iwamoto: Leading Technology of Bioanalysis and Protein Chemistry, SHIMADZU Corporation, Kyoto, Japan
    Takashi Shimada: Leading Technology of Bioanalysis and Protein Chemistry, SHIMADZU Corporation, Kyoto, Japan
    Minoru Matsuura: Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan
    Hiroshi Nakase: Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan
    Kazuo Matsubara: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
  • Abstract:

    Background

    Infliximab (IFX) is a chimeric mouse/human monoclonal antibody. IFX binds to tumor necrosis factor alpha (TNFα), and then suppresses the inflammation caused by certain autoimmune disorders, such as inflammatory bowel disease (IBD). Due to its immunogenicity, anti-drug antibodies (ADAs) are often produced in patients. Formation of

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 21 September 2019

FIP Congresses